Importantly for the diagnosis of GBM, the determination of IDH1 mutation status has been included, resulting in distinct subgroups, namely, IDH1 mutant type (IDH1 MUT) and IDH1 wild type (IDH1 WT), since the 2016 WHO classification of CNS tumors was released (6). This evidence concerns the gene IDH1 and central nervous system neoplasm.